BC008-1A
Phase 1Biologic
BC008-1A is one of 91 biologic programs targeting Glioma. It is currently in Phase 1.
2
Indications
2
Total Trials
2
Active Trials
90
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
225 competitors in Patients With Advanced Solid Tumors
#DrugCompanyPhaseTrials
1Taxol
TevaPhase 2
Avastin
RochePhase 2
Eloxatin
TevaPhase 2
Herceptin
RochePhase 2
Tecentriq
RochePhase 2
Camptosar
PfizerPhase 2
Lynparza
AstraZenecaPhase 2
Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Phase 2
Beyfortus
BeiGenePhase 2
Ibrance
PfizerPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BC008-1A. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details